中国药物经济学2024，Vol.19Issue(7)：5-11,15,8.DOI:10.12010/j.issn.1673-5846.2024.07.001
盐酸凯普拉生片治疗反流性食管炎的成本-效果
Cost-effectiveness of Kenuolazan Hydrochloride Tablets in the Treatment of Refluxc Esophagitis
程莉丽 1陈卓 2李自刚 2陈鑫 2曹珲3
作者信息
- 1. 江苏省医药行业协会,南京 210015
- 2. 复星医药(国内营销平台),上海 200233
- 3. 江苏柯菲平医药股份有限公司,南京 210015
- 折叠
摘要
Abstract
Objective To evaluate the effectiveness and economy of kenuolazan hydrochloride tablets in the treatment of patients with reflux esophagitis(RE).Methods Using RE patients as the research subjects,from the perspective of medical insurance payer,we construct a Markov model to simulate the health utility and direct medical costs under each reference regimen,evaluating the economy of kenuolazan regimen compared to vonoprazan regimen in the treatment of reflux esophagitis based on the Incremental Cost-effectiveness Ratio(ICER),and sensitivity analysis was performed to verify the stability of the results.Results The total cost of the kenuolazan regimen was RMB 2 225.40 with total QALYs of 1.082 81,and the total cost of the vonoprazan regimen was RMB 2 340.78 with total QALYs of 1.082 40.The ICER was-280 500.50 RMB/QALY.The factors in the sensitivity analysis had no significant impact on the study findings.Conclusion In the treatment of RE patients,the kenuolazan regimen has a clear advantage over the vonoprazan regimen.关键词
盐酸凯普拉生片/富马酸伏诺拉生片/反流性食管炎/成本-效果Key words
Kenuolazan hydrochloride/Vonoprazan fumarate/Reflux esophagitis/Cost-effectiveness分类
医药卫生引用本文复制引用
程莉丽,陈卓,李自刚,陈鑫,曹珲..盐酸凯普拉生片治疗反流性食管炎的成本-效果[J].中国药物经济学,2024,19(7):5-11,15,8.
